A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer

Summary

This is a single-arm, phase Ib/II study to examine the safety, tolerability and preliminary efficacy of one cycle of Ad-RTS-hIL-12 immunotherapy in women with advanced breast cancer and pre-study SD or PR after completion of a minimum 12 week course of standard first- or second-line chemotherapy. The patient population will include patients with locally advanced or metastatic breast cancer of all subtypes.

Timeline

Start

2015-07-18

Primary completion

2016-07-19

Completion

2016-07-19

Drugs

Indications